14 results about "Lymphatic tissues" patented technology

A spore of a bacillus subtilis B.subtilis WB600 strain is used as an antigen delivery carrier, spore coat protein C (CotC) is used as anchoring protein, a key protein ATPase gene and a CotC gene of micropterus salmoides iridovirus are fused through a gene fusion technology, a recombinant spore surface display system is constructed, the ATPase antigen is stably displayed on the spore surface, and an oral vaccine is prepared. After being orally applied to fishes, the vaccine can tolerate the gastrointestinal tract environment and is accurately delivered to intestinal related lymphatic tissues to stimulate fish immunity, and finally prevention and control of the iridovirus of the micropterus salmoides are achieved.

The invention discloses a culture method of in-vitro uniform monolayer cells of prawns, and belongs to the technical field of biology. The method comprises the following steps: (1) obtaining lymphatic tissues of a last-stage prawn at the early stage of shelling, completely stripping an outer membrane to obtain internal tissues, and cutting the internal tissues into small tissue blocks; (2) cleaning the small tissue blocks, inoculating the small tissue blocks to a culture plate coated with a gelatin solution, adding a complete culture solution into an inoculation system at intervals within 12 hours after inoculation for culture, replacing the complete culture solution 24-48 hours after inoculation, and inducing tissue cells to continuously migrate to form an in-vitro cell layer; (3) blowing and beating the cell culture to obtain a cell suspension, and centrifuging to obtain a cell monolayer; and (4) suspending the cell monolayer by adopting a complete culture solution, then inoculating the cell monolayer into a culture plate coated with a gelatin solution, and culturing to obtain the in-vitro uniform monolayer cells of the prawns. According to the method, the prawn monolayer cells which are long in in-vitro survival time, uniform and stable and are cultured in vitro can be obtained, and an important tool is provided for related virology research.

The present disclosure provides compositions and methods for the treatment and prevention of macrophage activation syndrome (MAS) or hemophagic lymphocyte hyperplasia (HLH). The methods involve administering to a patient in need thereof an antibody or fragment thereof that is specific for human GM-CSF protein.

A three-dimensional (3D) lymphoid tissue model is provided, the model including a cellularized stromal compartment and a plurality of cellularized compartments including lymphocytes disposed within the stromal compartment; and a controlled fluid perfusion system configured to perfuse the model with a perfusion fluid. Methods of fabricating a 3D lymphoid tissue model and producing antibodies with the 3D lymphoid tissue model are also provided.

The invention relates to a lymphatic tissue targeted composite nanocluster as well as a preparation method and application thereof. The composite nanocluster comprises Se-doped ZnS nanoparticles and BSA (Bovine Serum Albumin) coated on the surfaces of the nanoparticles. The nano platform for synergistically targeting lymphatic tissues integrates the complementary immunoregulation functions of zinc and selenium, overcomes the curative effect limitation of a single element through the synergistic effect of elements, and widens the safe treatment window of necessary trace elements; the natural lymph targeting characteristic of the serum albumin is utilized to realize efficient lymph node delivery of the nanocluster; meanwhile, the nano-cluster structure can promote in-vivo removal, so that long-term accumulation is reduced, and the safety is ensured.

The invention discloses a nasal delivery double-chain RNA / Mn < 2 + > nano-drug as well as a preparation method and application thereof in immunotherapy. And adding the polymer into a solution containing double-stranded RNA and manganese salt, and self-assembling to form the nasal delivery double-stranded RNA / Mn < 2 + > nano-drug. The invention provides a new technical scheme for the barrier of the BBB. The nano delivery system has the advantages in the aspects of overcoming the BBB and improving the in-vivo biological distribution of the drug, and the surface of the nano carrier is modified with a ligand targeted to an endothelial cell overexpression receptor, such as ApoE peptide and the like, so that the drug can be delivered to penetrate through the BBB; a non-invasive nasal-brain delivery strategy becomes a new scheme for improving drug availability and reducing toxic and side effects, the drug can bypass BBB and rapidly enter brain parenchyma through olfactory bulb and trigeminal nerve conduction pathways, and an immune drug delivered by the nasal cavity can rapidly enter nasopharynx-related lymphatic tissue (NALT) and is transferred to CLN through a lymphatic network around the nasal cavity, so that the immune drug can be rapidly delivered to the nasopharynx-related lymphatic tissue (NALT). Further, a potent local immune response aiming at the in-situ GBM is induced.

The invention discloses a diagnosis and treatment target device for cytophagic lymphocytosis. The device comprises a detection module, a detection module and a control module, wherein the detection module is used for detecting the expression quantity of four genes, namely CCR2, CDKN1A, TNFSF10 and TP53INP2 in a patient sample of a current patient; the detection module is used for detecting the expression quantity of four genes, namely CCR2, CDKN1A, TNFSF10 and TP53INP2; the analysis module is used for carrying out difference analysis on the expression quantity and the expression quantity of a healthy control group to obtain a molecular characteristic spectrum related to the HLH; the diagnosis typing treatment module is used for performing diagnosis typing on the current patient according to a difference mode of the molecular characteristic spectrum and treating according to a diagnosis typing result, so that serious treatment toxicity such as myelosuppression and liver and kidney injury of a traditional chemotherapy regimen can be reduced, the safety and effectiveness of clinical treatment of the patient are improved, and higher specificity and accuracy are achieved; a foundation is laid for developing a novel diagnostic tool, and a direct and feasible candidate scheme and a theoretical basis are provided for developing a high-efficiency and low-toxicity HLH new therapy.

This invention belongs to the field of biomedical technology and discloses the application of CCR2 inhibitors in the preparation of drugs for treating hemophagocytic lymphohistiocytosis (HLH). By establishing a mouse model of HLH, this invention reveals for the first time that CCR2 can serve as an effective drug target for treating HLH. Experiments showed that treatment with the CCR2-specific antagonist RS102895 significantly reduced splenomegaly, improved peripheral blood cell reduction, alleviated liver damage, corrected metabolic disorders in model mice, and effectively inhibited serum cytokine storm and abnormal activation of splenic macrophages. Based on these findings, CCR2 can serve as a novel target for HLH treatment, and its inhibitors can be used to prepare highly effective and low-toxicity drugs for treating HLH.

The application discloses an intelligent classification and identification method for ear-nose-throat lesion images, and relates to the technical field of image recognition, comprising the following steps: synchronously collecting a nasopharynx white light image and an i-Scan image, screening images meeting quality standards, associating pathology and grading annotation, and constructing a data set containing multi-center cases; carrying out denoising processing on the white light image and the i-Scan image respectively, extracting key landmark points and completing image registration, dividing mucosa surface area, submucosal blood vessel area and lymph tissue enrichment area through semantic segmentation, and carrying out feature enhancement on different areas; extracting morphological features and texture features from the enhanced images, calculating feature importance weights and fusing into low-dimensional feature vectors; constructing a benign and malignant binary classification model and a pathology type multi-classification model respectively, combining a physician diagnosis rule base and a verification index to output a classification result, and significantly improving the accuracy and clinical practicability of ear-nose-throat lesion diagnosis.

The invention discloses application of a conjunctiva-related lymphatic tissue index in diagnosis of dry eyes with sicca syndrome, and relates to the technical field of medical detection. A living body confocal microscope is used for observing and analyzing the morphological change of the conjunctival-related lymphatic tissue, a diagnostic model is established so as to assist in diagnosing SSDE, and the establishment method of the diagnostic model comprises the following steps: S1, preparing a subject; s2, IVCM inspection is carried out; s3, image processing and analysis; s4, data analysis; and S5, constructing a diagnosis model. Compared with the high cost of SS examination of all dry eye patients in referral, the method has the advantages that the CALT indexes are examined through IVCM, the patients needing to be further evaluated can be preliminarily screened out, and therefore unnecessary medical expenditure is reduced.

The present invention relates to the diagnosis and treatment of conditions in patients with elevated levels of CXCL9 and other biomarkers. Methods and compositions for the treatment of hemophagocytic lymphocytosis (HLH) are provided. The present disclosure also generally relates to methods and compositions for diagnosing and treating conditions associated with elevated levels of CXCL9, elevated levels of total IFN gamma, and other biomarkers. The present disclosure also relates to methods of treating, delaying the progression or otherwise ameliorating the symptom of a condition in a patient with elevated levels of CXCL9, elevated levels of total IFN gamma and other biomarkers using agents that intervene in or otherwise antagonize interferon gamma (IFN gamma) signaling, including neutralizing anti-IFN gamma antibodies.

To provide a pharmaceutical composition for use in the treatment of a disease selected from sepsis, secondary hemophagocytic lymphohistiocytosis, cytokine release syndrome, and systemic inflammatory response syndrome in a mammal in need thereof.SOLUTION: Provided is a pharmaceutical composition comprising a BTK inhibitor that is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.SELECTED DRAWING: None

The present disclosure provides compositions and methods for the treatment and prevention of Macrophage Activation Syndrome (MAS) or Hemophagocytic Lymphohistiocytosis (HLH). The methods involve administering to a patient in need thereof an antibody or fragment thereof specific for human GM-CSF protein.